Department of Medicine Posters

Follow

• 

  Follicular Bronchiolitis in an Adult Male with Common Variable Immune Deficiency

  Megan K. Ford, MD; Alana B. Kekevian, DO; Charalambos C. Solomides, MD; and John R. Cohn, MD, FACAAI

  BACKGROUND

  • Follicular bronchiolitis (FB) in patients with common variable immune deficiency (CVID) is rarely described and knowledge is based on case reports, case series, and studies on the individual disease entities.^1-5
  • FB is a granulomatous-lymphocytic interstitial lung disease (GLILD). GLILD is a group of non-infectious lung diseases which also includes lymphocytic interstitial pneumonia, granulomatous disease, and lymphoid hyperplasia.^6,7
  • FB is caused by an external stimulus or abnormal immune response that incites lymphoid hyperplasia.⁸
  • The etiology of FB is idiopathic or associated with collagen vascular disorders (e.g., Sjogrens, rheumatoid arthritis), hypersensitivity reactions, acquired immunodeficiencies (typically HIV), and less commonly, primary immunodeficiencies.^9,10 In case reports, FB has also been linked to primary ciliary dyskinesia, multicentric Castleman’s disease, primary tuberculosis, and eosinophilia with elevated IgE.^11-14
  • The differential diagnosis of FB includes other types of GLILD, low grade bronchus associated lymphoid tissue lymphoma, and sarcoidosis.¹

• 

  Detection of genetic and epigenetic DNA markers in urine for the early detection of primary and recurrent hepatocellular carcinoma

  Hie-Won Hann, Surbhi Jain, Ting-Tsung Chang, Chi-Tan Hu, Selena Lin, Wei Song, and Ying-Hsiu Su

  Poster presented at American Association of the Study of Liver Diseases (AASLD) meeting in San Francisco California.

  Objective:

  Develop a urine test using a panel of select genetic and epigenetic markers for the early detection of primary and recurrent HCC.

  Introduction:

  Hepatocellular carcinoma (HCC) or liver cancer is an aggressive disease and one of the fastest growing cancers by incidence in the United States. Early detection is the key for effective treatment of HCC as the 5-year survival rate is 26% in early stage HCC as compared to only 2% when found after spreading to distant organs. The current marker, alpha-feto protein (AFP) and its fucosylated glycoform, L3, are of limited value with only 40-60% sensitivity.